30
Participants
Start Date
September 16, 2010
Primary Completion Date
September 7, 2014
Study Completion Date
February 3, 2017
Bevacizumab
Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
Temozolomide
Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
RT (Radiation Therapy)
Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
University of Colorado Denver, University of Colorado Cancer Center, Aurora
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of Colorado, Denver
OTHER